Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Malignant Melanoma
U.S. Patent Received for Antigen Associated with Skin Cancer
November 24th, 1997
Cytoclonal Pharmaceutics Inc., Dallas, Texas, announced that it has received a U.S. Patent for an antigen (protein) associated with malignant melanoma, a form of skin cancer. The antigen and related proprietary monoclonal antibody are being developed for diagnosis and treatment of malignant melanoma. Skin cancer incidence continues to rise. An early diagnostic test could permit early intervention of this potentially lethal form of skin cancer. The melanoma antigen and related proprietary monoclonal antibody also are being developed as instruments for delivery of paclitaxel (Taxol) (marketed by Bristol-Myers Squibb) and other anti-cancer drugs to...
Source: Cancer Weekly (1997-11-24)
|
